Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vertex Pharmaceuticals Incorporated
With
ViroChem Pharma
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and Female subjects, 18-65 years of age (females non-child bearing potential in Part B)
Have laboratory evidence of HCV infection for 6 months, defined by (1) presence of anti-HCV antibody (Genotype 1a and 1b infection), or (2)documented HCV RNA presence by a sensitive and specific assay and (3 histologic evidence of CHC (Fibrosis on a standardized histological grading system)
Plasma HCV RNA of 100,000 IU/ml
HIV 1 and HIV2 ab seronegative
Body Mass Index (BMI) ≤ 35 kg/m2 BMI
Treatment Naive subjects
You may not be if
Contraindications to peginterferon or ribavirin therapy
Have evidence of liver cirrhosis, decompensated liver disease, and Child-Pugh score \> 5
Have hemoglobinopathies, unstable cardiac disease, history of organ transplant, active malignant disease or uncontrolled Type I or II diabetes
Clareo Health | Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection
